AN2 Therapeutics (ANTX) investor relations material

Pipeline overview and strategic focus

• Three clinical-stage assets in phase II proof-of-concept studies: polycythemia vera (PV), Mycobacterium abscessus, and Chagas disease, with two lacking any FDA-approved treatments.

• Additional research programs include two oncology assets targeting PI3 kinase and ENPP1, leveraging proprietary boron chemistry.

• Near-term data readouts expected for all three main programs starting in Q4 this year and continuing through next year.

Polycythemia vera (PV) program

• Phase II study for oral epetraborole to initiate in Q3, focusing on red cell-specific therapy to control hematocrit and reduce thrombotic risk.

• Study design includes a sentinel safety group, dose titration, and a placebo-controlled part with patient-reported outcomes.

• Enabling data show significant, controlled reduction in hematocrit without affecting white cells or platelets.

• High unmet need as over half of patients are not well-controlled with current therapies.

• Data from the open-label phase expected throughout 2027.

Mycobacterium abscessus program

• Phase II investigator-initiated trial underway with 84 patients, focusing on an oral regimen to replace current IV therapies.

• Epetraborole demonstrates high potency against clinical isolates and strong efficacy in animal models, comparable to gold-standard IV antibiotics.

• Differentiated by novel mechanism and lack of pre-existing resistance, with microbiological and patient-reported endpoints.

• Data expected late next year.